BackEnliven Therapeutics Overview
Enliven Therapeutics Inc

Enliven Therapeutics Target Price

Analysts' average 12-month price target for Enliven Therapeutics is $73.

Get informed when a big investor buys or sells

+ Follow

Share Price

$54.32

Average Target Price

$72.5033.5% upside

10 analysts in the last 4 months

High: $82 | Low: $60

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-18Mizuho SecuritiesSalim Syed$7334.4% upsideOpen
2026-08-18BarclaysEtzer Darout$7843.6% upsideOpen
2026-08-06Stifel NicolausDara Azar$8251% upsideOpen
2026-08-06GuggenheimMichael Schmidt$7843.6% upsideOpen
2026-08-06Goldman Sachs$8047.3% upsideOpen
2026-07-21Goldman SachsSalveen Richter$6723.3% upsideOpen
2026-07-09H.C. WainwrightRobert Burns$6519.7% upsideOpen
2026-07-01Stifel Nicolaus$8047.3% upsideOpen
2026-06-08Stifel Nicolaus$6010.5% upsideOpen
2026-06-02Mizuho SecuritiesSalim Syed$6214.1% upsideOpen
2026-05-12Guggenheim$8047.3% upsideOpen
2026-05-08Goldman Sachs$598.6% upsideOpen
2025-06-16Robert W. BairdColleen Kusy$524.3% downsideOpen
2025-03-21H.C. Wainwright$3928.2% downsideOpen
2024-11-15Robert W. BairdColleen Kusy$4026.4% downsideOpen
2024-09-23Mizuho SecuritiesSalim Syed$3928.2% downsideOpen
2024-06-10Robert W. BairdColleen Kusy$3241.1% downsideOpen
2024-04-09Mizuho SecuritiesSalim Syed$3437.4% downsideOpen

Enliven Therapeutics (ELVN) FAQ

Enliven Therapeutics (ELVN) currently reports a target price of $73. Use the charts on this page to explore Enliven Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Enliven Therapeutics is $73, about 33.5% upside from the current share price of $54.32. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $73, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Enliven Therapeutics, and consider following ELVN for alerts when major investors trade the stock.

Enliven Therapeutics is classified in the Healthcare sector. On target price, it currently shows $73. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ELVN with unrelated industries.